Modified Frailty Index for Minimally Invasive Distal Pancreatectomy

Status Completed

Clinical Trial Summary

This study aims to investigate the difference in postoperative complications according to the modified Frailty Index (mFI) in patients who underwent minimally invasive distal pancreatectomy for pancreatic tumors at the Asan Medical Center's Department of Hepato-Biliary-Pancreatic Surgery from 2005 to 2019. It also seeks to confirm the utility of mFI as a predictive factor for postoperative complications in frail patients in the future.

Clinical Trial Description

Distal pancreatectomy is a surgery performed to treat tumors in the distal pancreas. The minimally invasive approach to this surgery has become the standard due to its shorter hospital stay, quicker recovery, less pain, and similar complication rates compared to open surgery, especially for benign tumors. In selected patients with malignant tumors, minimally invasive distal pancreatectomy has gradually expanded to a state where it is not inferior to open surgery in terms of postoperative complications and long-term prognosis. As the average lifespan increases, elderly patients with comorbidities are steadily increasing in numbers among those who undergo distal pancreatectomy. However, predicting postoperative complications and mortality rates for these patients is still difficult. Simple yet effective predictive factors for postoperative complications are needed. The Canadian Study of Health and Aging has created a standardized frailty index (CSHA-FI) as a tool for predicting frailty in elderly patients, and a modified Frailty Index (mFI) has been developed for easy use. The mFI has been reported as a predictor of postoperative morbidity and mortality rates after colorectal and vascular surgery. This study aims to investigate whether mFI can be used as a predictive factor for postoperative morbidity and mortality rates in patients who undergo minimally invasive distal pancreatectomy and to utilize it for clinical treatment in the future. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05837793
Study type	Observational
Source	Asan Medical Center
Contact
Status	Completed
Phase
Start date	January 1, 2023
Completion date	April 10, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01141335` - Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair	Phase 4
Recruiting	`NCT02535039` - Methylprednisolone Combined Electric-acupuncture on Cognitive Function	Phase 1/Phase 2
Completed	`NCT02445300` - Efficacy of Wound Care and Reduction of Wound Complications by Use of AQUACEL® Ag Surgical Dressing in MIS TKA	Phase 4
Recruiting	`NCT03205189` - Comparison Between Pre-operative Prescription Delivered During Anesthesia Consultation or Post-operative Prescription	N/A
Not yet recruiting	`NCT02375269` - Effect of Remote Ischemic Preconditioning on Postoperative Complications in Visceral Surgery	N/A
Recruiting	`NCT01583751` - Videoendoscopic Pilonidal Sinus Surgery	Phase 1
Recruiting	`NCT02776046` - Individualized Perioperative Open-lung Ventilatory Strategy With High Versus Conventional Inspiratory Oxygen Fraction (iPROVE-O2).	N/A
Not yet recruiting	`NCT02838173` - Serratus Plane Block for the Prevention of Chronic Pain After Breast Cancer Surgery	N/A
Completed	`NCT01883752` - Goal Directed Fluid Management Based on Non-invasive Monitoring	N/A
Completed	`NCT02696122` - Quality of Recovery After General or Spinal Anesthesia for Inguinal Hernia Repair	N/A
Terminated	`NCT02062788` - Evaluation of Preoperative Oral Rehydration Solution in Colectomy	Phase 3
Withdrawn	`NCT00789659` - Incisional Wound Vac in Obese Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.